β-lactam activity against penicillin-resistant Streptococcus pneumoniae strains exhibiting higher amoxicillin versus penicillin minimum inhibitory concentration values: An in vitro pharmacodynamic simulation

Chemotherapy

Volumn 54, Issue 2, 2008, Pages 84-90

  Sevillano, D ^a   Aguilar, L ^a   Alou, L ^a   Gimenez M J ^a   Gonzalez N ^a   Echeverria O ^a   Torrico, M ^a   Valdes, L ^b   Coronel, P ^c   Prieto, J ^a,d  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b GLAXOSMITHKLINE   (Spain)

^c Tedec Meiji Farma SA   (Spain)

^d SCHOOL OF MEDICINE   (Spain)

Author keywords

Amoxicillin resistance; Amoxicillin clavulanic acid; Bactericidal activity; Cefditoren; Cefuroxime; Pharmacodynamic simulation; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CEFDITOREN PIVOXIL; CEFUROXIME AXETIL;

ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CULTURE MEDIUM; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SIMULATION; STREPTOCOCCUS PNEUMONIAE;

AMOXICILLIN; BETA-LACTAMS; BLOOD BACTERICIDAL ACTIVITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLIN RESISTANCE; PENICILLINS; STREPTOCOCCUS PNEUMONIAE;

EID: 41349096513     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000118659     Document Type: Article

References (22)

1. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C, Baquero F, Aguilar L, Dal-Ré R, García-de-Lomas J, the Spanish Surveillance Group for Respiratory Pathogens: Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005;49:1965-1972.
2. Perez-Trallero E, Marimon JM, Gonzalez A, García-Rey C, Aguilar L: Genetic relatedness of recently collected Spanish respiratory tract Streptococcus pneumoniae isolates with reduced susceptibility to amoxicillin. Antimicrob Agents Chemother 2003;47:3637-3639.
3. Doern GV: Antimicrobial use and the emergence of antimicrobial resistance with Streptococcus pneumoniae in the United States. Clin Infect Dis 2001;33(suppl 3):S187-S192.
4. National Committee for Clinical Laboratory Standards: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. Approved Standard M7-A6, ed 6. Wayne, NCCLS, 2003.
5. Sevillano D, Calvo A, Giménez MJ, Alou L, Aguilar L, Valero E, Carcas A, Prieto J: Bactericidal activity of amoxicillin against nonsusceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 2004;54:1148-1151.
6. Mulford D, Mayer M, Witt G: Effect of age and gender on the pharmacokinetics of cefditoren (poster 310). 40th Interscience Conference on Antimicrob Agents Chemother, Toronto, Sept 2000.
7. Mulford D, Mayer M, Witt G: Effect of renal impairment on the pharmacokinetic of cefditoren (poster 311): 40th Interscience Conference on Antimicrob Agents Chemother, Toronto, Sept 2000.
8. Finn A, Straughn A, Meyer M, Chubb J: Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos 1987;8:519-526.
9. Sommers DK, Van Wyk M, Williams PE, Harding SM: Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984;25:344-347.
10. Vree TB, Dammers E, Exler PS: Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob Chemother 2003;51:373-378.
11. Ferslew KE, Daigneault EA, Aten EM, Roseman JM: Pharmacokinetics and urinary excretion of clavulanic acid after oral administration of amoxicillin and potassium clavulanate. J Clin Pharmacol 1984;24:452-456.
12. Fraschini F, Scaglione F, Falchi M, Dugnani S, Mezzetti M, Cicchetti F, Alfano G, Pintucci GP: Pharmacokinetics and tissue distribution of amoxicillin plus clavulanic acid after oral administration in man. J Chemother 1990;2:171-177.
13. Burkhardt O, Borner K, von der Hoh N, Koppe P, Pletz MW, Nord CE, Lode H: Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002;50:707-712.
14. Andrews JM: Microbiological assays; in Reeves DS, Wise R, Andrews JM, White LO (eds): Clinical Antimicrobial Assays. Oxford, Oxford University Press, 1999.
15. Pérez-Trallero E, Marimón JM, Ercibengoa M, Giménez MJ, Coronel P, Aguilar L: Antimicrobial susceptibility of amoxicillin nonsusceptible versus susceptible isolates among penicillin non-susceptible Streptococcus pneumoniae. Clin Microbiol Infect 2007;13:937-940.
16. Joyanes P, Pascual A, Gimenez MJ, Garcia I, Aguilar L, Perea E: Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. Chemotherapy 2001;47:409-414.
17. Mueller M, De la Peña A, Derendorf H: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 2004;48:369-377.
18. Soriano F, Granizo JJ, Fenoll A, Gracia M, Fernandez-Roblas R, Esteban J, Gadea I, Coronel P, Gimeno M, Rodenas E, Santos F: Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae isolated in four Southern European countries (ARISE Project) from adult patients: results from the Cefditoren Surveillance Program. J Chemother 2003;15:107-112.
19. Fenoll A, Gimenez MJ, Robledo O, Coronel P, Gimeno M, Casal J, Aguilar L: Activity of cefditoren against clinical isolates of Streptococcus pneumoniae showing non-susceptibility to penicillins, cephalosporins, macrolides, ketolides or quinolones. Int J Antimicrob Agents 2007;29:224-226.
20. Jacobs MR: How can we predict bacterial eradication? Int J Infect Dis 2003;7(suppl 1):S13-S20.
21. Camacho MT, Casal J, Aguilar L, Gimenez MJ, Fenoll A: Very high resistance to amoxicillin in Streptococcus pneumoniae: an epidemiological fact or a technical issue? J Chemother 2006;18:303-306.
22. Habib MP: Management of clinical failures in non-ICU patients with chronic obstructive pulmonary disease exacerbations. Chemotherapy 2001;47(suppl 4):39-46.